WO2005074993A3 - Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden - Google Patents

Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden Download PDF

Info

Publication number
WO2005074993A3
WO2005074993A3 PCT/EP2005/001252 EP2005001252W WO2005074993A3 WO 2005074993 A3 WO2005074993 A3 WO 2005074993A3 EP 2005001252 W EP2005001252 W EP 2005001252W WO 2005074993 A3 WO2005074993 A3 WO 2005074993A3
Authority
WO
WIPO (PCT)
Prior art keywords
aldonic acid
derivative
polynucleotide
reacted
polynucleotides
Prior art date
Application number
PCT/EP2005/001252
Other languages
English (en)
French (fr)
Other versions
WO2005074993A2 (de
Inventor
Klaus Sommermeyer
Original Assignee
Noxxon Pharma Ag
Supramol Parenteral Colloid Gm
Klaus Sommermeyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag, Supramol Parenteral Colloid Gm, Klaus Sommermeyer filed Critical Noxxon Pharma Ag
Priority to KR1020067016012A priority Critical patent/KR101189555B1/ko
Priority to AU2005210142A priority patent/AU2005210142A1/en
Priority to US10/597,787 priority patent/US20090281296A1/en
Priority to JP2006552525A priority patent/JP5193468B2/ja
Priority to CN2005800044579A priority patent/CN1917905B/zh
Priority to EP05715273A priority patent/EP1713509A2/de
Priority to CA2555467A priority patent/CA2555467C/en
Priority to BRPI0507540-8A priority patent/BRPI0507540A/pt
Publication of WO2005074993A2 publication Critical patent/WO2005074993A2/de
Publication of WO2005074993A3 publication Critical patent/WO2005074993A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung eines Konjugates aus einem Polynukleotid und einem Polysaccharid umfassend die Schritte: a) Bereitstellen einer Aldonsäure des Polysaccharides oder eines Derivates davon; b) Umsetzen der Aldonsäure mit einem Alkohol-Derivat, bevorzugterweise einem Carbonat-Derivat eines Alkohols, zu einem Aldonsäure-Ester, bevorzugterweise zu einem aktivierten Aldonsäure-Ester; und c) Umsetzen des Aldonsäure-Esters mit dem Polynukleotid, wobei das Polynukleotid eine funktionale Amino-Gruppe aufweist, wobei das Umsetzen der Aldonsäure mit dem Alkohol-Derivat in Schritt (b) in einem trockenen aprotischen polaren Lösungsmittel erfolgt.
PCT/EP2005/001252 2004-02-09 2005-02-08 Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden WO2005074993A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020067016012A KR101189555B1 (ko) 2004-02-09 2005-02-08 폴리사카라이드 및 폴리뉴클레오티드로부터 접합체를제조하는 방법
AU2005210142A AU2005210142A1 (en) 2004-02-09 2005-02-08 Method for producing conjugates of polysaccharides and polynucleotides
US10/597,787 US20090281296A1 (en) 2004-02-09 2005-02-08 Process for the production of conjugates from polysaccharides and polynucelotides
JP2006552525A JP5193468B2 (ja) 2004-02-09 2005-02-08 多糖とポリヌクレオチドの複合体を製造する方法
CN2005800044579A CN1917905B (zh) 2004-02-09 2005-02-08 从多糖和多核苷酸生产缀合物的方法
EP05715273A EP1713509A2 (de) 2004-02-09 2005-02-08 Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden
CA2555467A CA2555467C (en) 2004-02-09 2005-02-08 Process for the production of conjugates from polysaccharides and polynucleotides
BRPI0507540-8A BRPI0507540A (pt) 2004-02-09 2005-02-08 processo para a produção de conjugados de polissacarìdeos e polinucleotìdeos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004006249 2004-02-09
DE102004006249.8 2004-02-09

Publications (2)

Publication Number Publication Date
WO2005074993A2 WO2005074993A2 (de) 2005-08-18
WO2005074993A3 true WO2005074993A3 (de) 2006-04-20

Family

ID=34832566

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001252 WO2005074993A2 (de) 2004-02-09 2005-02-08 Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden

Country Status (9)

Country Link
US (1) US20090281296A1 (de)
EP (1) EP1713509A2 (de)
JP (2) JP5193468B2 (de)
KR (1) KR101189555B1 (de)
CN (1) CN1917905B (de)
AU (1) AU2005210142A1 (de)
BR (1) BRPI0507540A (de)
CA (1) CA2555467C (de)
WO (1) WO2005074993A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5396019B2 (ja) * 2004-03-11 2014-01-22 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
PT2135949E (pt) 2006-02-14 2013-01-07 Noxxon Pharma Ag Ácidos nucleicos que se ligam à mcp-1
EP2407558A1 (de) 2006-10-31 2012-01-18 Noxxon Pharma AG Verfahren zum Nachweis eines einzel- oder doppelsträngigen Nukleinsäuremoleküls
WO2009040113A2 (en) 2007-09-24 2009-04-02 Noxxon Pharma Ag C5a BINDING NUCLEIC ACIDS
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
EP2561079A1 (de) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipidbindende nukleinsäuren
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
WO2012055573A1 (en) 2010-10-29 2012-05-03 Noxxon Pharma Ag Use of hepcidin binding nucleic acids for depletion of hepcidin from the body
KR20140026357A (ko) 2011-01-10 2014-03-05 녹손 파르마 아게 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법
CA2852802A1 (en) 2011-10-21 2013-04-25 Noxxon Pharma Ag Glucagon binding nucleic acids
WO2013104539A1 (en) 2012-01-10 2013-07-18 Noxxon Pharma Ag Nucleic acids specifically binding cgrp
WO2013104540A1 (en) 2012-01-10 2013-07-18 Noxxon Pharma Ag New c5a binding nucleic acids
WO2013113503A1 (en) 2012-01-31 2013-08-08 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and an oligonucleotide
RU2636465C2 (ru) 2012-02-09 2017-11-23 Лайф Текнолоджис Корпорейшн Способ конъюгирования полимерной частицы
JP6522496B2 (ja) 2012-05-16 2019-05-29 ノクソン ファーマ エージー Ｌ−核酸の酵素性合成
WO2015062743A1 (en) 2013-11-04 2015-05-07 Noxxon Pharma Ag Means and methods for the treatment of nephropathy
CN107922974B (zh) 2015-07-02 2021-11-09 生命技术公司 羧基官能亲水微珠的偶合
EP3320115B1 (de) 2015-07-06 2020-09-02 Life Technologies Corporation Substrat und verfahren zur sequenzierung
US11371045B2 (en) 2016-04-15 2022-06-28 Noxxon Pharma Ag Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
EP4306640A1 (de) 2022-06-21 2024-01-17 TME Pharma AG Verfahren zur behandlung eines tumors in einem patienten
WO2023247651A1 (en) 2022-06-21 2023-12-28 TME Pharma AG Methods for treating a tumor in a subject

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720663A (en) * 1971-06-24 1973-03-13 Nat Starch Chem Corp Preparation of starch esters
WO1994001448A1 (en) * 1992-07-06 1994-01-20 Pharmagenics, Inc. Oligonucleotides modified with conjugate groups
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
WO2002080979A2 (de) * 2001-03-16 2002-10-17 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-wirkstoff-konjugate
WO2003070772A1 (de) * 2002-02-20 2003-08-28 Fresenius Kabi Deutschland Gmbh Stärkederivate, stärke-wirkstoff-konjugate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10254745A1 (de) * 2002-11-23 2004-06-03 Supramol Parenteral Colloids Gmbh Imidazolide von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
WO2004050710A2 (de) * 2002-12-04 2004-06-17 Supramol Parenteral Colloids Gmbh Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen
DE10302520A1 (de) * 2003-01-23 2004-08-05 Supramol Parenteral Colloids Gmbh Kohlensäurediester von Stärkefraktionen und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809112B1 (fr) * 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
WO2001090253A1 (de) * 2000-05-23 2001-11-29 Dyomics Gmbh Stabile nir-marker-farbstoffe auf der basis von benzopyrylium-polymethinen
ATE469164T1 (de) * 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720663A (en) * 1971-06-24 1973-03-13 Nat Starch Chem Corp Preparation of starch esters
WO1994001448A1 (en) * 1992-07-06 1994-01-20 Pharmagenics, Inc. Oligonucleotides modified with conjugate groups
WO1997021452A2 (en) * 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
WO2002080979A2 (de) * 2001-03-16 2002-10-17 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-wirkstoff-konjugate
WO2003070772A1 (de) * 2002-02-20 2003-08-28 Fresenius Kabi Deutschland Gmbh Stärkederivate, stärke-wirkstoff-konjugate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE10254745A1 (de) * 2002-11-23 2004-06-03 Supramol Parenteral Colloids Gmbh Imidazolide von Polysaccharid Aldonsäuren, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe
WO2004050710A2 (de) * 2002-12-04 2004-06-17 Supramol Parenteral Colloids Gmbh Aldonsäure-ester, verfahren zu ihrer herstellung und verfahren zur herstellung von mit polysacchariden oder polysaccharid-derivaten an freien aminogruppen gekoppelten pharmazeutischen wirkstoffen
DE10302520A1 (de) * 2003-01-23 2004-08-05 Supramol Parenteral Colloids Gmbh Kohlensäurediester von Stärkefraktionen und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung zur Kopplung an pharmazeutische Wirkstoffe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAGINAKA J ET AL: "Separation of enantiomers on a chiral stationary phase based on ovoglycoprotein - I. Influences of the pore size of base silica materials and bound protein amounts on chiral resolution", JOURNAL OF CHROMATOGRAPHY A, ELSEVIER, AMSTERDAM, NL, vol. 773, no. 1-2, 27 June 1997 (1997-06-27), pages 85 - 91, XP004125495, ISSN: 0021-9673 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
WO2005074993A2 (de) 2005-08-18
JP2007522164A (ja) 2007-08-09
KR101189555B1 (ko) 2012-10-16
AU2005210142A1 (en) 2005-08-18
KR20060132906A (ko) 2006-12-22
EP1713509A2 (de) 2006-10-25
CA2555467C (en) 2012-10-09
CN1917905A (zh) 2007-02-21
US20090281296A1 (en) 2009-11-12
JP5193468B2 (ja) 2013-05-08
BRPI0507540A (pt) 2007-07-03
CN1917905B (zh) 2012-01-04
JP2013056889A (ja) 2013-03-28
CA2555467A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2005074993A3 (de) Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden
WO2008015239A3 (en) Muteins of tear lipocalin and methods for obtaining the same
WO2006058092A3 (en) Monosaccharide production system
WO2007066232A3 (en) Salts of fatty acids and methods of making and using thereof
WO2007000343A3 (en) Process for manufacturing vaccines
WO2005037320A3 (en) Process for preparing polysaccharide-protein conjugate vaccines
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
NO20053179D0 (no) Aldonsyreestere, fremgangsmater for fremstilling derav og fremgangsmater for fremstilling av farmasoytisk aktive ingredienser som er bundet til polysakkarider eller polysakkarid-derivater pa frie aminogrupper.
WO2007021960A3 (en) Polymer compositions and processes for making and using same
WO2005106008A3 (en) Enzymatic decarboxylation of 2-keto-l-gulonic acid to produce xylose
WO2006026104A3 (en) Crosslinking of hyaluronan solutions and nanofibrous membranes made therefrom
EP1921141A4 (de) Neues künstliches basenpaar und verwendung davon
WO2005123140A3 (en) Preparation of macromolecular conjugates by four-component condensation reaction
WO2008147396A3 (en) Method for improving yield of cellulose conversion processes
WO2005121206A3 (en) Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group and sulfonic acid group, and production method thereof
WO2007029003A3 (en) Method of preparing a hydrogel
WO2005062933A3 (en) Method of connecting rigid bodies and rigid body
WO2009097471A3 (en) Improving the appearance of nails
WO2009150543A3 (en) Conjugated vi saccharides
WO2008096547A1 (ja) 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物
WO2005121204A3 (en) Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor
WO2008013735A8 (en) Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
EA200601351A1 (ru) Способ получения сложных моноэфиров многоатомных спиртов
WO2008011033A3 (en) Synthesis of isotopically labeled alpha-keto acids and esters
WO2009004951A1 (ja) セルロースを含む材料の加水分解および酵素糖化による単糖類の製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005715273

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4427/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2555467

Country of ref document: CA

Ref document number: 1020067016012

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006552525

Country of ref document: JP

Ref document number: 200580004457.9

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005210142

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005210142

Country of ref document: AU

Date of ref document: 20050208

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005210142

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005715273

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067016012

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0507540

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10597787

Country of ref document: US